Imperial Prostate
@ip-london.bsky.social
A collective of expert urologists, medical specialists, and experienced researchers working to change the way the world diagnoses and treats prostate disease
April 29, 2025 at 4:09 PM
Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
April 29, 2025 at 8:28 AM
Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸
Take home - these treatments are safe and justified
Recruitment for the main trial has completed - PFS endpoint to be reported 2027
Take home - these treatments are safe and justified
Recruitment for the main trial has completed - PFS endpoint to be reported 2027
April 28, 2025 at 9:03 AM
Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸
Take home - these treatments are safe and justified
Recruitment for the main trial has completed - PFS endpoint to be reported 2027
Take home - these treatments are safe and justified
Recruitment for the main trial has completed - PFS endpoint to be reported 2027
Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan
Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸
Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸
April 28, 2025 at 9:00 AM
Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan
Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸
Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸
@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease
Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸
Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸
April 27, 2025 at 9:49 AM
@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease
Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸
Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸
5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸
Take home message - 3 of 4 patients were free of retreatment by 5 years
Take home message - 3 of 4 patients were free of retreatment by 5 years
April 27, 2025 at 9:44 AM
5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸
Take home message - 3 of 4 patients were free of retreatment by 5 years
Take home message - 3 of 4 patients were free of retreatment by 5 years
Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate
Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!
#AUA25 🇺🇸
Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!
#AUA25 🇺🇸
April 27, 2025 at 9:39 AM
Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate
Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!
#AUA25 🇺🇸
Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!
#AUA25 🇺🇸
New publication alert! 🚨
A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)
🔗 doi.org/10.1177/2051...
A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)
🔗 doi.org/10.1177/2051...
April 27, 2025 at 9:28 AM
New publication alert! 🚨
A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)
🔗 doi.org/10.1177/2051...
A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)
🔗 doi.org/10.1177/2051...
👀🤏🏽 We're squeezing a few more in! 🚨Registrations for the Imperial Prostate & Focal Therapy Society Masterclass 2025 close at midnight on Sunday 06/04 - secure your spot now before it's too late! ✨
View the agenda 🔗 www.imperialprostatemasterclass.org
#IPFTSmasterclass25
View the agenda 🔗 www.imperialprostatemasterclass.org
#IPFTSmasterclass25
Imperial Prostate Masterclass
www.imperialprostatemasterclass.org
April 4, 2025 at 2:21 PM
👀🤏🏽 We're squeezing a few more in! 🚨Registrations for the Imperial Prostate & Focal Therapy Society Masterclass 2025 close at midnight on Sunday 06/04 - secure your spot now before it's too late! ✨
View the agenda 🔗 www.imperialprostatemasterclass.org
#IPFTSmasterclass25
View the agenda 🔗 www.imperialprostatemasterclass.org
#IPFTSmasterclass25
📢 Join us at @IP_London
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
Description
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...
www.imperial.ac.uk
April 2, 2025 at 11:29 AM
📢 Join us at @IP_London
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.
@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social
www.lbc.co.uk/opinion/view...
@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social
www.lbc.co.uk/opinion/view...
I treat prostate cancer every day – now I'm launching a study that could transform screening and save lives
The debate on screening for prostate cancer has been raging for over two decades.
www.lbc.co.uk
March 28, 2025 at 11:14 AM
💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.
@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social
www.lbc.co.uk/opinion/view...
@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social
www.lbc.co.uk/opinion/view...
#IP2ATLANTA RCT pilot result #EAU25 🇪🇸
🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce
🚦Early signal in prostate cancer mortality for cytoreductive arms
📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!
@connorurol.bsky.social
🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce
🚦Early signal in prostate cancer mortality for cytoreductive arms
📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!
@connorurol.bsky.social
March 24, 2025 at 12:57 PM
#IP2ATLANTA RCT pilot result #EAU25 🇪🇸
🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce
🚦Early signal in prostate cancer mortality for cytoreductive arms
📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!
@connorurol.bsky.social
🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce
🚦Early signal in prostate cancer mortality for cytoreductive arms
📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!
@connorurol.bsky.social
Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op
Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!
#EAU25 🇪🇸
Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!
#EAU25 🇪🇸
March 24, 2025 at 11:16 AM
Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op
Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!
#EAU25 🇪🇸
Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!
#EAU25 🇪🇸
It’s a big last day at #EAU25 for our team! 🇪🇸
@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)
Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)
Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)
@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)
Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)
Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)
March 24, 2025 at 9:13 AM
It’s a big last day at #EAU25 for our team! 🇪🇸
@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)
Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)
Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)
@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)
Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)
Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)
Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session
Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
March 23, 2025 at 5:55 PM
Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session
Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
Excellent presentation by Miss Yan Leung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸
75% retreatment-free at 5 years and the majority satisfied with their treatment!
75% retreatment-free at 5 years and the majority satisfied with their treatment!
March 23, 2025 at 3:18 PM
Excellent presentation by Miss Yan Leung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸
75% retreatment-free at 5 years and the majority satisfied with their treatment!
75% retreatment-free at 5 years and the majority satisfied with their treatment!
And now @londonprostate1.bsky.social presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25
March 23, 2025 at 12:15 PM
And now @londonprostate1.bsky.social presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25
👀 @IP_London @ #EAU25 today!
Real world experience of Rezūm therapy (≥ 80g) - retreatment rates at 5 years follow up - Miss Yan Leung
📍Green Area EGPT1
⏱️ 15:30
Outcomes of focal HIFU for localised PCa determined by modern risk stratification strategies - Ms Deepika Reddy
📍Green Area Rm3
⏱️ 17:15
Real world experience of Rezūm therapy (≥ 80g) - retreatment rates at 5 years follow up - Miss Yan Leung
📍Green Area EGPT1
⏱️ 15:30
Outcomes of focal HIFU for localised PCa determined by modern risk stratification strategies - Ms Deepika Reddy
📍Green Area Rm3
⏱️ 17:15
March 23, 2025 at 11:40 AM
👀 @IP_London @ #EAU25 today!
Real world experience of Rezūm therapy (≥ 80g) - retreatment rates at 5 years follow up - Miss Yan Leung
📍Green Area EGPT1
⏱️ 15:30
Outcomes of focal HIFU for localised PCa determined by modern risk stratification strategies - Ms Deepika Reddy
📍Green Area Rm3
⏱️ 17:15
Real world experience of Rezūm therapy (≥ 80g) - retreatment rates at 5 years follow up - Miss Yan Leung
📍Green Area EGPT1
⏱️ 15:30
Outcomes of focal HIFU for localised PCa determined by modern risk stratification strategies - Ms Deepika Reddy
📍Green Area Rm3
⏱️ 17:15
Reposted by Imperial Prostate
📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out!
Live on Monday 12:00 ⏱️ #EAU25 🇪🇸
#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social
Live on Monday 12:00 ⏱️ #EAU25 🇪🇸
#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social
March 22, 2025 at 10:11 AM
📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out!
Live on Monday 12:00 ⏱️ #EAU25 🇪🇸
#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social
Live on Monday 12:00 ⏱️ #EAU25 🇪🇸
#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social